MX2022005869A - Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado. - Google Patents
Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado.Info
- Publication number
- MX2022005869A MX2022005869A MX2022005869A MX2022005869A MX2022005869A MX 2022005869 A MX2022005869 A MX 2022005869A MX 2022005869 A MX2022005869 A MX 2022005869A MX 2022005869 A MX2022005869 A MX 2022005869A MX 2022005869 A MX2022005869 A MX 2022005869A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- treatment
- gene therapy
- specific gene
- therapy vectors
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 229940122601 Esterase inhibitor Drugs 0.000 abstract 2
- 239000002329 esterase inhibitor Substances 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 108091006086 inhibitor proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935359P | 2019-11-14 | 2019-11-14 | |
| US202063016365P | 2020-04-28 | 2020-04-28 | |
| PCT/US2020/060337 WO2021097157A1 (en) | 2019-11-14 | 2020-11-13 | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005869A true MX2022005869A (es) | 2022-06-14 |
Family
ID=73834586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005869A MX2022005869A (es) | 2019-11-14 | 2020-11-13 | Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230340078A1 (https=) |
| EP (1) | EP4058475A1 (https=) |
| JP (1) | JP2023503850A (https=) |
| KR (1) | KR20220098210A (https=) |
| CN (1) | CN114829391A (https=) |
| AU (1) | AU2020384294A1 (https=) |
| BR (1) | BR112022009279A2 (https=) |
| CA (1) | CA3161154A1 (https=) |
| CL (1) | CL2022001260A1 (https=) |
| CO (1) | CO2022005641A2 (https=) |
| IL (1) | IL292717A (https=) |
| MX (1) | MX2022005869A (https=) |
| TW (1) | TW202128733A (https=) |
| WO (1) | WO2021097157A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230407328A1 (en) | 2020-11-02 | 2023-12-21 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
| WO2022165027A2 (en) * | 2021-01-27 | 2022-08-04 | Spark Therapeutics, Inc. | Compositions and methods for treating hereditary angioedema |
| JP2024523891A (ja) * | 2021-06-17 | 2024-07-02 | メイラグティーエックス ユーケー アイアイ リミティド | Ａａｖ産生方法 |
| AR127217A1 (es) | 2021-10-01 | 2023-12-27 | Biomarin Pharm Inc | Tratamiento de angioedema hereditario con vectores de genoterapia de aav y formulaciones terapéuticas |
| CN117947040A (zh) | 2022-10-31 | 2024-04-30 | 苏州荷光科汇生物科技有限公司 | 用于目的基因的表达盒及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58011B1 (en) | 1983-05-27 | 1993-06-16 | Texas A & M Univ Sys | Method for producing a recombinant baculovirus expression vector |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US7323324B2 (en) | 2001-10-16 | 2008-01-29 | National Institute Of Advanced Industrial Science And Technology | N-Acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| AU2013221212B2 (en) | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
| KR20240090694A (ko) * | 2013-07-22 | 2024-06-21 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
| RS61039B1 (sr) * | 2013-09-12 | 2020-12-31 | Biomarin Pharm Inc | Aav vektori koji sadrže gen koji kodira faktor viii |
| JP6573991B2 (ja) * | 2015-05-28 | 2019-09-11 | コーネル ユニヴァーシティー | 血管性浮腫の治療としてのｃ１ｅｉのアデノ随伴ウイルス介在性送達 |
| PE20190401A1 (es) | 2016-07-26 | 2019-03-13 | Biomarin Pharm Inc | Novedosas proteinas de la capside del virus adenoasociado |
| KR20200122320A (ko) * | 2018-01-16 | 2020-10-27 | 씨엘에스 테라퓨틱스 리미티드 | 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료 |
| US20210379203A1 (en) * | 2018-10-26 | 2021-12-09 | Vrije Universiteit Brussel | New Tools for Improving Gene Therapy and Use Thereof |
| EP4048800A1 (en) * | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
-
2020
- 2020-11-13 CN CN202080087888.0A patent/CN114829391A/zh active Pending
- 2020-11-13 WO PCT/US2020/060337 patent/WO2021097157A1/en not_active Ceased
- 2020-11-13 MX MX2022005869A patent/MX2022005869A/es unknown
- 2020-11-13 US US17/777,690 patent/US20230340078A1/en not_active Abandoned
- 2020-11-13 TW TW109139830A patent/TW202128733A/zh unknown
- 2020-11-13 JP JP2022527987A patent/JP2023503850A/ja active Pending
- 2020-11-13 BR BR112022009279A patent/BR112022009279A2/pt not_active IP Right Cessation
- 2020-11-13 CA CA3161154A patent/CA3161154A1/en active Pending
- 2020-11-13 EP EP20824369.1A patent/EP4058475A1/en not_active Withdrawn
- 2020-11-13 KR KR1020227019436A patent/KR20220098210A/ko active Pending
- 2020-11-13 AU AU2020384294A patent/AU2020384294A1/en not_active Abandoned
-
2022
- 2022-04-29 CO CONC2022/0005641A patent/CO2022005641A2/es unknown
- 2022-05-03 IL IL292717A patent/IL292717A/en unknown
- 2022-05-13 CL CL2022001260A patent/CL2022001260A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292717A (en) | 2022-07-01 |
| JP2023503850A (ja) | 2023-02-01 |
| KR20220098210A (ko) | 2022-07-11 |
| AU2020384294A1 (en) | 2022-06-02 |
| EP4058475A1 (en) | 2022-09-21 |
| BR112022009279A2 (pt) | 2022-09-06 |
| TW202128733A (zh) | 2021-08-01 |
| CN114829391A (zh) | 2022-07-29 |
| CA3161154A1 (en) | 2021-05-20 |
| CL2022001260A1 (es) | 2023-03-10 |
| US20230340078A1 (en) | 2023-10-26 |
| WO2021097157A1 (en) | 2021-05-20 |
| CO2022005641A2 (es) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005869A (es) | Tratamiento del angioedema hereditario con vectores de terapia de genes especificos del higado. | |
| AU2018372763A1 (en) | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| WO2019016772A3 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| WO2018154380A8 (en) | Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disorders | |
| MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
| WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| MX2018014256A (es) | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. | |
| BRPI0517135A (pt) | composições e métodos para tratar doenças neoplásticas | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| HK1252542A1 (zh) | 改进的尿酸酶序列和治疗方法 | |
| PH12022552009A1 (en) | Compositions and methods for kallikrein ( klkb1) gene editing | |
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| MX2021008503A (es) | Tratamiento de enfermedades que involucran deficiencia de enpp1 o enpp3. | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2025002182A (es) | Terapias de combinacion que usan inhibidores de proteina arginina n-metil transferasa 5 (prmt5) e inhibidores de la familia del oncogen de linfoma de celulas b 2 (bcl-2) para el tratamiento del cancer | |
| AR120461A1 (es) | Tratamiento del angioedema hereditario con vectores de terapia de genes específicos del hígado | |
| WO2020185651A3 (en) | Compositions and methods for treating huntington's disease | |
| MX2023001764A (es) | Composiciones y métodos para tratar o prevenir el angioedema hereditario. |